Application of Wearable Technology in High-risk Surgical Patients in the Perioperative Period

Sponsor
Mater Misericordiae University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05642988
Collaborator
Health Service Executive, Ireland (Other)
30
1
7
4.3

Study Details

Study Description

Brief Summary

Unrecognised changes in patients' vital signs after surgery can result in preventable complications. Current standard practice includes routine monitoring of patient vital signs up until hospital discharge.

Upon discharge from hospital, all forms of routine vital sign monitoring ceases. The availability and use of wearable technology in healthcare is increasing rapidly. The role of wearable technology in the remote monitoring of patients at high-risk of post-operative complications and hospital readmission after discharge from hospital is unclear.

This pilot study is aimed to assess the feasibility of using wearable technology in patients recovering from major intracavity surgery after hospital discharge in the Irish healthcare setting.

Condition or Disease Intervention/Treatment Phase
  • Device: LifeSignals 1AX Biosensor

Detailed Description

Patients undergoing major abdominal and pelvic surgery can have re-admission rates of over 20% in the first 90-days after surgery.

In Ireland the 30-day mortality following emergency abdominal surgery is 6.6%, and 90-day mortality 11.6% (1). Furthermore, 20% of post-operative deaths occur after hospital discharge in those over 80 years of age, of which over 95% occurs during the first six-weeks (2).

Despite this high risk, many patients are discharged home from hospital when medically fit and continuous monitoring discontinues. In hospital, patient monitoring is routine to identify patient deterioration at an early stage using the national early warning score (NEWS), which consists of the following clinical observations: heart rate, blood pressure, temperature, respiratory rate, oxygen saturation and level of consciousness. This monitoring is done routinely in the hospital ward at least every four hours. This monitoring stops when patients are discharged from hospital. Patients discharged are given general advice for recovery and, as part of current practice, are advised to contact their GP or emergency department if feeling unwell. Despite this, mortality in the post-discharge period accounts for nearly a quarter of all post-operative deaths.

Home monitoring of patients with chronic conditions has previously been shown to be of some utility. Recently, during the COVID-19 pandemic, remote home monitoring of patients diagnosed with COVID-19 who did not meet hospital admission criteria were managed by smartphone application and peripheral pulse oximetery.

To date, no previously published studies have adopted home monitoring for a patient group that is at a high risk of re-admission. In addition, simple questionnaires used to monitor postoperative recovery (such as the QoR-15) exist, that are reflective of a patient's current health status, but they have not been used to monitor patients after hospital discharge.

In this study, the investigators aim to test the feasibility and patient compliance of remote wearable biosensor technology monitoring after major intracavity surgery. The remote monitoring combines vital sign observations (ECG, heart rate, temperature and respiratory rate) and a health status assessment questionnaire.

The study protocol has been approved by the Mater Misericordiae University Hospital Institutional Review Board (IRB) (Reference: 1/378/2207). Any protocol modifications will be submitted for the IRB review and approval.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Application of Wearable Technology in High-risk Surgical Patients in the Perioperative Period: a Feasibility Study
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Adult patients being discharged from hospital following intra-abdominal or pelvic surgery

Patient compliance with wearable biosensor monitoring after major intracavity surgery. The remote monitoring is made up of a wearable biosensor and a data-enabled relay device which will detect vital sign observations (ECG, heart rate, temperature and respiratory rate) and a health status assessment questionnaire.

Device: LifeSignals 1AX Biosensor
Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital

Outcome Measures

Primary Outcome Measures

  1. Primary Objective [30-days]

    Assess compliance with remote monitoring in the first 30-days after hospital discharge following intra-abdominal or pelvic surgery. Compliance will be defined as wearing the biosensor for at least 20 hours per day.

Secondary Outcome Measures

  1. Secondary Outcome [30-days]

    Retrospectively explore how recorded vital signs relate to any unplanned hospital admission or GP visits in the first 30-days after hospital discharge. The 30-day questionnaire performed will be the Quality of Recovery 15 (QoR-15) score

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Over 18 years of age

  • Scheduled to undergo or recently undergone major intra-cavity abdominal surgery

  • Able to give informed written consent to participate

Exclusion Criteria:
  • Deemed unfit for surgery

  • Unable or unwilling to comply with remote monitoring for any reason

  • Unable or unwilling to fill in a questionnaire in English

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mater Misericordiae University Hospital Dublin 7 Ireland

Sponsors and Collaborators

  • Mater Misericordiae University Hospital
  • Health Service Executive, Ireland

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pádraig Ó Scanaill, Consultant Anaesthetist, Mater Misericordiae University Hospital
ClinicalTrials.gov Identifier:
NCT05642988
Other Study ID Numbers:
  • 1/378/2207
First Posted:
Dec 8, 2022
Last Update Posted:
Dec 9, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 9, 2022